zolpidem (zole-pi-dem)

Ambien, Ambien CR, Edluar, Intermezzo, \(\text{\textregistered}\) Sublinox, Zolpimist

Classification
Therapeutic: sedatives/hypnotics
Schedule IV

Pregnancy Category C

Indications
Insomnia with difficulties in sleep initiation (Intermezzo is indicated for insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep).

Action
Produces CNS depression by binding to GABA receptors. Has no analgesic properties.

Therapeutic Effects: Sedation and induction of sleep.

Pharmacokinetics

Absorption: Rapidly absorbed following oral administration. Controlled-release formulation releases 10 mg immediately, then another 2.5 mg later.

Distribution: Minimal amounts enter breast milk; remainder of distribution not known.

Metabolism and Excretion: Converted to inactive metabolites, which are excreted by the kidneys; clearance of Intermezzo lower in women than in men.

Half-life: 2.5–3 hr (\(\text{\textregistered}\) in geriatric patients and patients with hepatic impairment).

TIME/ACTION PROFILE (sedation)

<table>
<thead>
<tr>
<th>ROUTE</th>
<th>ONSET</th>
<th>PEAK</th>
<th>DURATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>PO</td>
<td>rapid</td>
<td>30 min–2 hr</td>
<td>6–8 hr</td>
</tr>
<tr>
<td>PO-ER</td>
<td>rapid</td>
<td>2–4 hr</td>
<td>6–8 hr</td>
</tr>
<tr>
<td>PO-Spray</td>
<td>rapid</td>
<td>unknown</td>
<td>unknown</td>
</tr>
<tr>
<td>SL</td>
<td>rapid</td>
<td>unknown</td>
<td>unknown</td>
</tr>
</tbody>
</table>

*Food delays peak levels and effects

Contraindications/Precautions

Contraindicated in: Hypersensitivity, Sleep apnea.

Use Cautiously in: History of previous psychiatric illness, suicide attempt, drug or alcohol abuse; Hepatic impairment (initial dose \(\text{\textregistered}\) recommended); Pulmonary disease; Myasthenia gravis; Geri: Initial dose \(\text{\textregistered}\) recommended; GB; Lactation: Safety not established.

Adverse Reactions/Side Effects

CNS: dizziness, vivid dreams, abnormal dreaming, agitation, amnesia, behavior changes, “dreaming” feeling, hallucinations, sleep-driving.

GI: diarrhea, nausea, vomiting.

Misc: ophthalmia, hypertension, urticaria, physical dependence, psychological dependence, tolerance.

Interactions

Drug-Drug: CNS depression may occur with sedatives/hypnotics, alcohol, phenothiazines, tricyclic antidepressants, opioid analgesics, or antihistamines.

Drug-Natural Products: Concomitant use of kava-kava, valerian, or chamomile can cause CNS depression.

Drug-Food: Food may delay absorption.

Route/Dosage

PO, SL (Adults): Tablets, spray, or SL tablets (Edluar)—5 mg (for women) and 5–10 mg (for men) at bedtime; may be increased to 10 mg at bedtime if 5–mg dose not effective; SL tablets (Intermezzo)—1.75 mg (for women) or 3.5 mg (for men) once upon awakening in the middle-of-the-night; Extended-release tablets—6.25 mg (for women) and 6.25–12.5 mg (for men) at bedtime; may be increased to 12.5 mg at bedtime.

PO, SL (Geriatric Patients, Debilitated Patients, or Patients with Hepatic Impairment): Tablets, spray or SL tablets (Edluar)—Do not exceed dose of 5 mg at bedtime; Extended-release tablets—Do not exceed dose of 6.25–12.5 mg at bedtime; SL tablets (Intermezzo)—Do not exceed dose of 1.75 mg at bedtime (in either men or women).

NURSING IMPLICATIONS

Assessment

- Assess mental status, sleep patterns, and potential for abuse prior to administration. Prolonged use of \(\text{\textregistered}\) 10 days may lead to physical and psychological dependence; limit amount of drug available to the patient.

- Assess withdrawal symptoms: peak effect. Notify health care professional if desired sedation does not occur.

○ = Generic drug name
□ = Genetic Implication
*OPTIS indicates risk of drug interaction; underline indicates most frequent
\(\text{\textregistered}\) discontinued
Assess patient for pain. Medicate as needed. Untreated pain decreases sedative effects.

Potential Nursing Diagnoses
Insomnia (Indications)
Risk for injury (Side Effects)

Implementation
Before administering, reduce external stimuli and provide comfort measures to increase effectiveness of medication.
Use lowest effective dose.
PO: Tablets should be swallowed whole with full glass of water. For faster onset of sleep, do not administer with or immediately after a meal.
Swallow extended-release tablets whole; do not crush, break, or chew.
SL: To open the blister pack, separate the individual blisters at the perforations. Peel off top layer of paper and push tablet through foil. Place the tablet under the tongue, allow to disintegrate; do not swallow or take with water.
Intermezzo: Only take if at least 4 hr left prior to time to awaken.
Oral Spray: Do not take with or immediately after a meal. Spray is a clear, colorless, and cherry-flavor solution.

Patient/Family Teaching
Instruct patient to take zolpidem as directed. Advise patient not to take zolpidem unless able to stay in bed a full night (7–8 hours) before being active again. Do not take more than the amount prescribed. Be aware of habit-forming potential. Not recommended for use longer than 7–10 days. If used for 2 wk or longer, abrupt withdrawal may result in fatigue, nausea, flushing, light-headedness, uncontrolled crying, vomiting, GI upset, panic attack, or nervousness. Instruct patient to read Patient Information for correct product before taking and with each Rx refill, changes may occur.
Because of rapid onset, advise patient to go to bed immediately after taking zolpidem.
May cause drowsiness or dizziness. Advise patient to avoid driving, or other activities requiring alertness until response to this medication is known.

Caution patient that complex sleep-related behaviors (sleep-driving) may occur. Advise patient to notify health care professional immediately if signs of anaphylaxis (swelling of the tongue or throat, trouble breathing, and nausea and vomiting) occur.
Caution patients to avoid consumption of alcohol or other CNS depressants.
Oral Spray: To prime, patients should be told to point the black spray opening away from their face and other people and spray 5 times. For administration, hold container upright with the black spray opening pointed directly into the mouth. Press down lidly on pump to make sure a full dose (5 mg) is sprayed directly into mouth over tongue. For 10-mg dose, a second spray should be administered. If not used for 14 days, re-prime with 1 spray.

Evaluation/Desired Outcomes
Relief of insomnia.
Re-evaluate insomnia after 7–10 days of Intermezzo.

Why was this drug prescribed for your patient?